Unilife Corp

Unilife — Piper Jaffray Healthcare Conference 2014

15 slides from Unilife's conference presentation, Dec 2, 2014

  1. Slide 1: Piper Jaffray Healthcare Conference

    Slide 1: Piper Jaffray Healthcare Conference

    Exhibit 99.1 Piper Jaffray Healthcare Conference December 2, 2014 Confidential-Unilife Corporation

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements Thispresentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward-looking statements are based on management’s beliefs and assumptions and on information currently available to our manag

  3. Slide 3: Investment Highlights

    Slide 3: Investment Highlights

    Investment Highlights Prefilled Syringes Reconstitution Systems Auto-Injectors Wearable Injectors Ocular Systems Novel Systems A broad portfolio of innovative, differentiated, customizable products Injectable drug delivery systems Leveraged by customers to enhance and differentiate injectable therap

  4. Slide 4: A Selection of Unilife Customers

    Slide 4: A Selection of Unilife Customers

    A Selection of Unilife Customers As of Sep 30, 2014 Unilife had 15 active programs* with multiple customers across all product platforms. Most programs remain confidential at this time. 4 Confidential-Unilife Corporation * Includes announced supply agreements

  5. Slide 5: Our Annuity-Like Business Model

    Slide 5: Our Annuity-Like Business Model

    Our Annuity-Like Business Model A broad portfolio Long-term Supply direct to of innovative customer supply pharmaceutical product platforms agreements companies Avg. 10-15 year supply Customizable product B2B model with well agreements provide platforms with market- defined list of current and conti

  6. Slide 6: Delivering Brilliance. Together with our Customers.

    Slide 6: Delivering Brilliance. Together with our Customers.

    Delivering Brilliance. Together with our Customers. Creating Value. Minimizing Risk. Addressing Customer Needs. Pharmaceutical or Drug-Device Unilife Biotech Company Combination Product • A broad market-driven • Large portfolios of • Building therapy compliance portfolio of customizable, biologics,

  7. Slide 7: Participating in Large, Fast-Growing Markets

    Slide 7: Participating in Large, Fast-Growing Markets

    Participating in Large, Fast-Growing Markets Injectable Drug Delivery Systems Device Market Growth* by Segment2015- 2025 Market Segment CAGR * ASP* $18,000 Prefilled Syringes 8% $0.5 -$2 $16,000 (ready-to-fill syringes) $14,000 Wearable Injectors 105% $25-$35 (Wearable, disposable systems) $12,000 R

  8. Slide 8: A Broad, Flexible Portfolio for all Injectable Therapies

    Slide 8: A Broad, Flexible Portfolio for all Injectable Therapies

    A Broad,FlexiblePortfolio for all InjectableTherapies* Unifill® Unifill Finesse™ Unifill Select™ Unifill Allure ™ Unifill Nexus™ AutoMix Presto™ EZMix Genesis™ EZMix Engage™ EZMix Prodigy™ RITA™ LISA™ Precision-Therapy™ Flex-Therapy™ Ocu-mix™ Depot-ject™ Ocu-ject™ Micro-ject™ * Excluding insulin. Pr

  9. Slide 9: Commercial Supply Agreements for Unifill

    Slide 9: Commercial Supply Agreements for Unifill

    Commercial Supply Agreements for Unifill ® • Global supply agreement for Lovenox Global supply agreement for initial target list of • • World’s largest selling prefilled drug 20 generics • Supply agreement extending out to 2024 • 15 year duration with 175MM minimum unit purchase volumes • Payments o

  10. Slide 10: Supply Agreements for Wearable Injectors

    Slide 10: Supply Agreements for Wearable Injectors

    Supply Agreements for Wearable Injectors 15-Year commercial supply agreement • Long-term commercial supply agreement Unilife sole provider of wearable injectors with biologics R&D arm MedImmune for all Sanofi’s applicable drugs • Unilife to customize and supply devices Platform also offered for mole

  11. Slide 11: The Magnitude of our Supply Agreements

    Slide 11: The Magnitude of our Supply Agreements

    The Magnitude of our Supply Agreements Unifill Unifill Wearable injectors Wearable injectors Finesse platform 15-Years Long-term (not disclosed) 10-Years 15-Years 5-10 biologics* Several biologics Min. 150MM Min. 175MM units^ annually units^ annually Average 5MM units annually per wearable injector

  12. Slide 12: Today's agreement for Depot-ject

    Slide 12: Today's agreement for Depot-ject

    Today’s agreement for Depot-ject™ Details of the Agreement Worldwide 10-year commercial supply agreement with global pharmaceutical company for use with approved therapy Treatmentof visionimpairment associatedwith a highprevalencediseaseof the retina Intravitreal injection for sustained release into

  13. Slide 13: A Large, Growing Commercial Pipeline

    Slide 13: A Large, Growing Commercial Pipeline

    A Large, Growing Commercial Pipeline Additional agreements generate incremental revenue growth Commercial Active Commercial Pipeline Programs supply •Multiple pharma •11 additional •Initial key and biotech programs* as of Sep agreements inc. companies 30, 2014 •Sanofi (wearable •Many approved •Spann

  14. Slide 14: Scaling up to meet Accelerating Demand

    Slide 14: Scaling up to meet Accelerating Demand

    Scaling up to meet Accelerating Demand York, Pennsylvania • 160,000 sq. ft. FDA-registered state-of-the-art manufacturing facility • Commercial supply underway and will accelerate through 2016-2017 • Pre-approval for facility expansion to support accelerating demand Four continents 30 countries • Th

  15. Slide 15: Delivering Brilliance.

    Slide 15: Delivering Brilliance.

    Delivering Brilliance. Redefining the Market for Injectable Drug Delivery Systems • The most extensive, market-driven portfolio for injectable therapies • Signing long-term commercial supply agreements with many of the largest, most innovative pharmaceutical and biotech companies • Agreements to gen

Source: SEC EDGAR · 8-K filed Dec 2, 2014

More decks from Unilife Corp